Home › NDC Lookup › RxCUI directory › RxCUI 2375325

Solifenacin succinate 1 MG/ML Oral Suspension [Vesicare] — RxCUI 2375325

RxNorm drug concept · Semantic branded drug
RxCUI 2375325 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2375325
Official nameSolifenacin succinate 1 MG/ML Oral Suspension [Vesicare]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVesicare 1 MG/ML Oral Suspension; VESIcare LS 5 MG in 5 mL Oral Suspension; Vesicare LS 5 MG per 5 ML Oral Suspension
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)726 prescriptions · 8 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Solifenacin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It helps calm an overactive bladder. If you're rushing to the bathroom constantly, waking up at night to urinate, or sometimes not making it in time, solifenacin works by blocking...
  • What exactly is solifenacin supposed to do for me?
  • Dry mouth is the most common side effect, and it's more noticeable at higher doses. Sipping water throughout the day, chewing sugar-free gum, or using a saliva substitute can all h...
  • The dry mouth is really bothering me — is there anything I can do?
📖 Read our full Solifenacin guide →

🕸️ Concept Web — How Solifenacin succinate 1 MG/ML Oral Suspension [V... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Solifenacin succinate 1 MG/ML Oral Suspension [Vesicare] RxCUI 2375325

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Solifenacin 322167
    • Solifenacin succinate 476588
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vesicare 539812
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Solifenacin Oral Suspension 2375320
    • Solifenacin succinate Oral Suspension 2648467
    • Solifenacin Oral Liquid Product 2375319
    • Solifenacin Oral Product 1159949
    • Solifenacin succinate Oral Liquid Product 2663359
    • Solifenacin succinate Oral Product 2661426
    • Solifenacin Oral Suspension [Vesicare] 2375323
    • Solifenacin succinate Oral Suspension [Vesicare] 2657580
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Solifenacin succinate 1 MG/ML Oral Suspension SCD · 2375321
  • Solifenacin succinate 1 MG/ML SCDC · 2375318
  • Solifenacin Oral Suspension SCDF · 2375320
  • Solifenacin succinate Oral Suspension SCDFP · 2648467
  • Solifenacin Oral Liquid Product SCDG · 2375319
  • Solifenacin Oral Product SCDG · 1159949
  • Solifenacin succinate Oral Liquid Product SCDGP · 2663359
  • Solifenacin succinate Oral Product SCDGP · 2661426

Brand-Name Concepts

  • Solifenacin succinate 1 MG/ML [Vesicare] SBDC · 2375322
  • Solifenacin Oral Suspension [Vesicare] SBDF · 2375323
  • Solifenacin succinate Oral Suspension [Vesicare] SBDFP · 2657580
  • Vesicare Oral Liquid Product SBDG · 2375324
  • Vesicare Oral Product SBDG · 1187116
  • Vesicare BN · 539812

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2375325 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
51248-0250-99 1 BOTTLE, PLASTIC in 1 CARTON (51248-250-99) / 150 mL in 1... VESIcare LS Astellas Pharma US, Inc. 2020-05-26
Observed labelers: Astellas Pharma US, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$1.6383
Range $1.6383–$1.6383 · middle 50% $1.6383–$1.6383 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.